How Pregnant Women and Their Babies Metabolize Ondansetron Compared to a Group of Non-pregnant Women

Model scores of the 29,894 trials active now.

Model score 13% for any early termination, 7% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 18% of the time (283 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2013-05-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Primary purpose: not given (lowers risk) · Design
• Sponsor's past termination rate: 12.5% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1/2 (raises risk) · Design
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: plannedundergoingnonsurgerytime
  Phrases that lowered it: healthyparticipanttermdrugmetabolism
• Number of arms: 3 (lowers risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 95 (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 23.3% (raises risk) · Drug's FDA history
• Disease area, neurology: No (lowers risk) · Disease area
• Blinding: none (raises risk) · Design
• Design: parallel (raises risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Drug's FAERS reports marked serious: 93.3% (raises risk) · Drug's FDA history
• Sponsor's past trials: 295 (lowers risk) · Sponsor's track record
• Collaborators: 0 (raises risk) · Design
• Drug's FAERS reports before start: 9744 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Can Ondansetron Prevent Neonatal Abstinence Syndrome (NAS) in Babies Born to Narcotic-dependent Women NCT01965704 · started 2014 · scored riskier than 58% of active trials completed
• Oxytocin and Brain Responses in Maternal Addiction NCT02979093 · started 2017 · scored riskier than 8% of active trials terminated
• A Phase III Efficacy and Safety Study of Intravenous Retosiban Versus Placebo for Women in Spontaneous Preterm Labor NCT02377466 · started 2016 · scored riskier than 64% of active trials terminated
• Placebo-controlled Trial of Bupropion for Smoking Cessation in Pregnant Women NCT02188459 · started 2014 · scored riskier than 18% of active trials completed
• A Study to Learn How the Study Medicine Called Zavegepant is Taken Up Into Blood and Breast Milk of Healthy Breast-Feeding Women NCT06453356 · started 2024 · scored riskier than 6% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.